Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It primarily develops drugs for the treatment of insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes, and other neurological and endocrine related diseases and disorders. The company's primary clinical development program, Indiplon, is a drug for the treatment of insomnia. Its Phase II clinical trial products include GnRH Antagonist for the treatment of endometriosis; CRF R1 Antagonist for mood disorders and irritable bowel syndrome; and CRF R2 Peptide Agonist�Urocortin 2 for cardiovascular diseases. Neurocrine's Phase I clinical trial products comprise Selective norepinephrine reuptake inhibitor (sNRI) for the treatment of neuropathic pain and GnRH Antagonist for the treatment of benign prostatic hyperplasia. Its products under research include sNRI for depression, stress, and urinary incontinence; glucose dependent insulin secretagogues for type II diabetes; Adenosine2A Receptor Antagonists for Parkinson's disease; and Ion Channel Blocker for the treatment of chronic pain. The company has collaboration with Pfizer to develop and commercialize Indiplon. Neurocrine was incorporated in 1992 and is based in San Diego, California.